CLINICAL_TRIALS
trial_result
· 2020-03-31
Clinical Trial Update: The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer [Phase 4]
Summary
Phase 4 trial evaluating BEPREVE 1.5% on tear film osmolarity and lipid layer in allergic conjunctivitis completed with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Minnesota Eye Consultants, P.A. | Conditions: Allergic Conjunctivitis | Phase 4 | Status: COMPLETED | Results posted: 2020-03-31